05:24 PM EST, 12/19/2024 (MT Newswires) -- Aclaris Therapeutics ( ACRS ) filed a registration statement with the US Securities and Exchange Commission Thursday covering the potential resale of up to about 35.6 million common shares of the company by certain stockholders.

The company issued the shares to the shareholders in a November private placement, according to a regulatory filing.

Aclaris shares were up nearly 7% in after-hours activity.